The a2 Milk Company Limited (NZX: ATM) Organisational Announcement

The a2 Milk Company wishes to advise that Chief People, Safety and Sustainability Officer, Lisa Burquest, has advised of her resignation from her role effective 31 January 2021.

Lisa joined the company in November 2018 and since then has worked with the rest of the Executive Leadership Team to build capability, capacity, performance and engagement through its people, whilst continuing to evolve the unique culture of The a2 Milk Company.

CEO Geoff Babidge said: “I’d personally like to thank Lisa for her contribution and wish her well for her future endeavours.”

Lisa will be taking up the role of Chief People Officer for Virgin Australia on 1st February which will allow her to leverage her experience in managing large workforces undergoing transformation and change.

A search for Lisa’s replacement will commence shortly.

See the link below for more details:

Organisational Announcement

Source: The a2 Milk Company Limited

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Meridian Energy monthly operating report for July 2022
Cannasouth to launch a pro-rata renounceable rights issue
August 12th Morning Report
2022 Annual Shareholders' Meeting & Director Nominations
Rakon 2022 Annual Meeting Chair's Address and Presentation
VHP - Full year results release
RAKON FY23 Earnings Guidance
August 11th Morning Report
Deferral of FDA consideration of enforcement discretion
MHJ - Response to ASX Query